Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

123.47USD
28 Apr 2017
Change (% chg)

$-0.27 (-0.22%)
Prev Close
$123.74
Open
$123.85
Day's High
$123.90
Day's Low
$123.13
Volume
4,381,766
Avg. Vol
6,612,288
52-wk High
$129.00
52-wk Low
$109.32

JNJ

Chart for JNJ

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $334,713.81
Shares Outstanding(Mil.): 2,710.89
Dividend: 0.84
Yield (%): 2.72

Financials

  JNJ Industry Sector
P/E (TTM): 20.76 29.08 30.08
EPS (TTM): 5.95 -- --
ROI: -- 13.73 13.25
ROE: -- 14.68 14.41

Lazard profit beats estimates as deal-making picks up

Lazard Ltd reported a higher-than-expected quarterly profit, mainly driven by growth in its financial advisory business as cross-border mergers and acquisitions got off to the strongest start in a decade.

Apr 27 2017

UPDATE 4-Lazard profit beats estimates as deal-making picks up

* Shares rise 2.3 pct (Adds Breakingviews link, updates share price)

Apr 27 2017

BRIEF-J&J increase qtrly dividend by 5 pct to $0.84 per share

* Johnson & johnson announces dividend increase of 5.0 percent

Apr 27 2017

Stroke drug Xarelto, plastics lift Bayer earnings

FRANKFURT Bayer raised its annual core earnings forecast on Thursday after beating expectations with a 15 percent quarterly advance helped by plastics unit Covestro and sales of stroke-prevention pill Xarelto in Europe and Japan.

Apr 27 2017

UPDATE 2-Stroke drug Xarelto, plastics lift Bayer earnings

* Shares up 3 percent to 11 month high (Adds detail on Xarelto, shares, analyst comment)

Apr 27 2017

J&J, Takeda among interested in Brazil's Hypermarcas: sources

SAO PAULO Johnson & Johnson , Novartis AG and Takeda Pharmaceutical Co Ltd have expressed interest in a buyout of the controlling stake that two families have in Brazilian drugmaker Hypermarcas SA , two people with knowledge of the matter said on Monday.

Apr 24 2017

UPDATE 4-J&J, Takeda among interested in Brazil's Hypermarcas, sources say

SAO PAULO, April 24 Johnson & Johnson, Novartis AG and Takeda Pharmaceutical Co Ltd have expressed interest in a buyout of the controlling stake that two families have in Brazilian drugmaker Hypermarcas SA , two people with knowledge of the matter said on Monday.

Apr 24 2017

J&J, Novartis and Takeda in talks for Brazil's Hypermarcas, sources say

SAO PAULO, April 24 Johnson & Johnson, Novartis AG and Takeda Pharmaceutical Co Ltd are in talks with the controlling bloc of Brazilian drugmaker Hypermarcas SA for a buyout, two people with knowledge of the matter said on Monday.

Apr 24 2017

J&J grabs 92.62 pct Actelion stake in provisional tender results

* Says Janssen Holding GmbH, a Swiss subsidiary of Johnson & Johnson, published the provisional notice of the end result of its all-cash public tender offer in Switzerland to acquire all publicly held shares of Actelion Ltd

Apr 24 2017

FDA approves Samsung Bioepis' copy of J&J's Remicade: company

SEOUL South Korea's Samsung Bioepis Co Ltd said on Saturday the U.S. Food and Drug Administration approved its copy of Johnson & Johnson's rheumatoid arthritis drug Remicade, the first drug developed by the Samsung Group unit approved in the United States.

Apr 21 2017

More From Around the Web

Earnings vs. Estimates